TPI ASM8: Completed Phase I enrollment

Topigen completed enrollment in a double-blind, placebo-controlled, European Phase II (TPI ASM8-205) trial evaluating inhaled TPI ASM8 for 14 days. The study was originally designed to enroll 18 patie...